waveRAPID® - The New Way of Measuring Kinetics

Dr. Kaspar Cottier founded Creoptix in 2009 and since then is fully dedicated to push the technology from a research stage to a commercial success. Before Creoptix, Kaspar was at Optrel AG in Wattwil, Switzerland, where he first worked as Optics Engineer and Deputy Director R&D, and later as Director Operations responsible for production, supply chain and process engineering.

Kaspar obtained his diploma (M.Sc. degree) in micro-engineering with specialization in optics from the Swiss Federal Institute of Technology Lausanne (EPFL) and his PhD from the University of Neuchatel, Switzerland, on the topic of label-free waveguide-grating sensors.

Dr. Michael Hennig studied Physics and Biochemistry, received the Ph.D. in structural biology at EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed two years postdoc work at the Biozentrum, University of Basel, Switzerland and 20 years of work in pharmaceutical industry at Roche, Basel, Switzerland. Finally, he was Global Head and Principle Leader of discovery technologies with responsibility for structure-based drug discovery, protein science, assay development and HTS, Roche corporate compound library, stem cell platform and analytical physical methods. In 2015, he co-founded leadXpro, a corporation dedicated to structure-based drug discovery for membrane protein targets (GPCR’s, Ion-channels, Transporter) and utilizing most advanced technologies such as the X-ray free electron laser (at PSI, SwissFEL) and cryo-electron microscopy (at University of Basel, cryo-EM) and biophysics methods such as provided by Creoptix.

Nicolas holds a PhD degree in Neuroscience from the University Pierre et Marie Curie (Pasteur Institute) in Paris. After a postdoc at the Friedrich Miescher Institute for Biomedical Research in Basel, he joined Roche to work on the development of biophysical methods for membrane proteins. At leadXpro, he combines his expertise and experience to gather structural information and decipher ligand-binding mechanisms on membrane protein targets using grating-coupled interferometry (GCI) technology.

Helena is a Professor of Biochemistry at Uppsala University in Sweden since 2002 and Chief Scientific Officer of Beactica AB. Specialist in enzymology and enzyme-based drug discovery with a focus on biomolecular interaction analysis for detailed studies of enzyme-inhibitor interactions and other important recognition processes in the life science area. The work has involved studies of a variety of enzymes, primarily proteases and polymerases from viruses and other infectious organisms, or involved in important disease processes. Extensive experience of the commercial drug discovery process through 20 years of collaborative research with partners in pharmaceutical and biotechnological industry.